All peptides discussed in this guide are sold by Webber Science for in vitro research purposes only.
Introduction
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog and the only FDA-approved peptide specifically indicated for the treatment of HIV-associated lipodystrophy (marketed as Egrifta/Egrifta SV). This unique regulatory status, combined with its potent visceral adipose tissue (VAT) reduction effects, makes it one of the most clinically validated metabolic peptides available for research.
Mechanism of Action
Tesamorelin is a 44-amino acid peptide structurally analogous to endogenous GHRH, with a trans-3-hexenoic acid modification at the N-terminus that increases resistance to dipeptidyl peptidase-4 (DPP-4) degradation.
Primary pathway:
1. Binds GHRH receptors on anterior pituitary somatotrophs
2. Stimulates pulsatile growth hormone (GH) release
3. GH acts on hepatic GHR receptors to increase IGF-1 production
4. GH/IGF-1 axis activation drives lipolysis in visceral adipose tissue
Key mechanistic features:
- DPP-4 resistance — The hexenoic acid modification extends half-life to ~2–3 hours vs ~30 minutes for native GHRH
- Pulsatile GH release — Preserves physiological GH pulsatility versus continuous elevation, which is metabolically significant
- Preferential VAT reduction — Preferentially reduces visceral rather than subcutaneous adipose tissue, a distinct advantage over many peptides
Research Evidence
HIV-Associated Lipodystrophy (FDA-Approved Indication)
- Phase 3 trials — Two 26-week randomized, double-blind, placebo-controlled trials (n=816) demonstrated statistically significant VAT reduction
- VAT reduction — -18% to -20% from baseline vs +1% in placebo group (p<0.001)
- Sustained effect — In the extension study, VAT reduction was maintained through 52 weeks with continued treatment
- Reversal on cessation — VAT returned toward baseline within 12 weeks of stopping treatment, indicating effect is maintenance-dependent
Metabolic Research Beyond HIV
- Insulin sensitivity — Paradoxical: reduces visceral fat (insulin-sensitizing) while GH elevation can transiently decrease insulin sensitivity. Net effect in clinical studies was neutral to slightly positive for glucose metabolism
- Lipid panels — Modest improvements in triglycerides and total cholesterol in sub-analyses
- Body composition — Preferential trunk fat reduction with relative preservation of lean mass
- Cardiovascular markers — CVD risk factor profile improvement primarily driven by VAT reduction
Emerging Research Areas
- NAFLD/NASH — Pilot studies suggest VAT reduction improves hepatic steatosis markers
- Cognitive function — Small studies exploring GH/IGF-1 axis effects on cognitive aging
- Bone density — GH/IGF-1’s anabolic effects on bone are an active research area
Comparison with Other GHRH/GH Peptides
| Feature | Tesamorelin | CJC-1295 (No DAC) | CJC-1295 (with DAC) | Ipamorelin |
|———|————-|——————–|——————–|————-|
| Class | GHRH analog | GHRH analog | GHRH analog (long-acting) | GHS (ghrelin mimetic) |
| Half-life | ~2-3 hours | ~30 min | ~6-8 days (albumin-bound) | ~2 hours |
| GH pattern | Pulsatile (physiologic) | Pulsatile | Sustained elevation | Pulsatile |
| FDA status | Approved (HIV lipodystrophy) | Research only | Research only | Research only |
| VAT specificity | High (preferential) | Moderate | Moderate | Low |
| Insulin effect | Neutral to slight decrease | Slight decrease | Can decrease sensitivity | Neutral/mild improvement |
For GHRH peptide comparisons, see our CJC-1295 guide and CJC-1295 DAC vs No DAC comparison.
Research Protocol Considerations
Reconstitution and Dosing
- Reconstitution: Use bacteriostatic water; standard 2mg vial reconstitution
- Use our peptide calculator for reconstitution and dosing math
- Storage: Lyophilized at -20°C; reconstituted solutions stable 2–4 weeks refrigerated
- See our reconstitution guide for detailed methodology
Study Design Considerations
- Primary endpoints: VAT measurement via DXA or CT; IGF-1 levels; body composition
- Duration: Clinical studies used 26-week primary endpoints; shorter pilot studies (8–12 weeks) may be appropriate for mechanistic endpoints
- Control comparisons: Consider vehicle control, CJC-1295, or GHRH comparator groups
Frequently Asked Questions
How does tesamorelin differ from CJC-1295?
Both are GHRH analogs, but tesamorelin has an N-terminal hexenoic acid modification (improving DPP-4 resistance), is FDA-approved for a specific indication, and has the strongest clinical evidence for VAT reduction. CJC-1295 with DAC has a much longer half-life (6–8 days via albumin binding) which creates sustained rather than pulsatile GH elevation.
Does tesamorelin affect blood sugar?
In clinical studies, tesamorelin showed a neutral to slightly positive net effect on glucose metabolism. The VAT reduction (insulin-sensitizing) largely offset GH-induced transient insulin resistance. Individual responses vary.
Why is tesamorelin the only FDA-approved peptide in this category?
Tesamorelin was developed specifically for HIV-associated lipodystrophy, a condition with significant unmet medical need. The FDA approval (2010) was based on robust phase 3 data through the Egrifta clinical programme. Other GHRH analogs have not pursued FDA approval for this or other indications.
Related Research Guides
- Weight Loss & Metabolic Peptides Guide
- HGH Peptides Guide
- CJC-1295 Complete Guide
- CJC-1295 DAC vs No DAC
- AOD9604 Research Guide
Buy Tesamorelin for research →
Disclaimer: Tesamorelin is provided by Webber Science for in vitro research purposes only. Egrifta is a registered trademark of Theratechnologies Inc. Not intended for human consumption, diagnosis, or treatment.